The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial-Reference-Cited by-同舟云学术

The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial

Published:2022-09-20 Issue:12 Volume:45 Page:2008-2017
ISSN:0916-9636
Container-title:Hypertension Research
language:en
Short-container-title:Hypertens Res

Author:

Yoo Tae-Hyun,Hong Soon Jun,Kim Sunggyun,Shin Seokjoon,Kim Dong Ki,Lee Jung Pyo,Han Sang Youb,Lee Sangho,Won Jong Chul,Kang Young Sun,Park Jongha,Han Byoung-Geun,Na Ki-Ryang,Hur Kyu Yeon,Kim Yong-Jin,Park Sungha

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Link

https://www.nature.com/articles/s41440-022-01028-6.pdf

Reference22 articles.

1. Hong YA, Ban TH, Kang CY, Hwang SD, Choi SR, Lee H, et al. Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS). Kidney Res Clin Pract. 2021;40:52–61.

2. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281–7.

3. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542–9.

4. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164–76.

5. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–20.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood pressure control in diabetic kidney disease: a post-hoc analysis of the FANTASTIC trial;Clinical Hypertension;2024-08-01

2. 2023 update and perspectives;Hypertension Research;2023-09-15

3. A Narrative Review of Signaling Pathway and Treatment Options for Diabetic Nephropathy;Current Molecular Medicine;2023-07-27

4. Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States;Cureus;2023-06-21